Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Short-term Investments (2016 - 2025)

ImmunityBio (IBRX) has disclosed Short-term Investments for 11 consecutive years, with $154.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments rose 2321.0% to $154.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $154.5 million, a 2321.0% increase, with the full-year FY2025 number at $154.5 million, up 2321.0% from a year prior.
  • Short-term Investments was $154.5 million for Q4 2025 at ImmunityBio, down from $197.6 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $197.6 million in Q3 2025 to a low of $931000.0 in Q1 2025.
  • A 5-year average of $46.7 million and a median of $17.2 million in 2024 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: tumbled 98.21% in 2023, then surged 3489.67% in 2024.
  • ImmunityBio's Short-term Investments stood at $136.0 million in 2021, then crashed by 98.13% to $2.5 million in 2022, then tumbled by 60.32% to $1.0 million in 2023, then surged by 532.41% to $6.4 million in 2024, then surged by 2321.0% to $154.5 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Short-term Investments are $154.5 million (Q4 2025), $197.6 million (Q3 2025), and $16.0 million (Q2 2025).